Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results

Aclaris Therapeutics (NASDAQ:ACRS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04, FiscalAI reports. The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.

Aclaris Therapeutics Stock Performance

Shares of ACRS stock traded down $0.07 during mid-day trading on Thursday, hitting $3.61. 2,328,009 shares of the stock were exchanged, compared to its average volume of 2,222,003. The stock’s fifty day simple moving average is $4.72 and its two-hundred day simple moving average is $4.53. Aclaris Therapeutics has a 12-month low of $2.10 and a 12-month high of $6.60. The stock has a market capitalization of $504.76 million, a price-to-earnings ratio of -6.22 and a beta of 0.96.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ACRS shares. Wedbush dropped their price objective on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Wednesday, October 28th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday, October 28th. Canaccord Genuity Group boosted their target price on Aclaris Therapeutics from $10.00 to $13.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Finally, Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $11.33.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.